ROLE OF SUSTAINED-RELEASE CALCIUM ANTAGONIST (AMLODIPINE MALEATE) IN THE TREATMENT OF ESSENTIAL HYPERTENSION IN PATIENTS WITH ASTHMA

Cover Page

Cite item

Full Text

Abstract

Objective: to evaluate the efficacy, vasoprotective properties, and safety of amlodipine maleate used in patients with asthma concurrent with
essential hypertension (EH).


Subjects and methods. Twenty asthmatic patients in remission with grade I–II EH were examined. The patients were given amlodipine maleate (Stamlo® M, Dr. Reddy’s Laboratories) in a daily dose of 5–10 mg for an antihypertensive purpose. External respiration tests, 24-hour blood pressure monitoring, and studies of endothelial vasomotor function and arterial elastic properties were performed in patients at baseline and after a 6-month course of therapy.


Results. The good tolerability and safety of amlodipine maleate were ascertained in patients with asthma concurrent with EH, irrespective of the severity of bronchoobstructive syndrome and the degree of asthma control. These trials demonstrate not only the obvious antihypertensive effects of amlodipine maleate, but also its vasoprotective properties: its beneficial effect on endothelial vasoregulatory function and vascular wall rigidity.


Conclusion. The findings confirm that it is expedient to use Stamlo® M in patients with asthma concurrent with EH.

About the authors

N. A. Karoli

V.I. Razumovsky Saratov State Medical University, Russian Agency for Health Care

Department of Hospital Therapy Russian Federation

A. A. Roshchina

V.I. Razumovsky Saratov State Medical University, Russian Agency for Health Care

Department of Hospital Therapy Russian Federation

A. P. Rebrov

V.I. Razumovsky Saratov State Medical University, Russian Agency for Health Care

Author for correspondence.
Email: rebrov@sgu.ru
Department of Hospital Therapy Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2011



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36931 от  21.07.2009.